Ultragenyx (RARE)

NASDAQ
78.40
+1.44(+1.87%)
After Hours
78.37
-0.03(-0.04%)
- Real-time Data
  • Volume:
    527,165
  • Bid/Ask:
    69.29/80.00
  • Day's Range:
    77.37 - 80.01

RARE Overview

Prev. Close
76.96
Day's Range
77.37-80.01
Revenue
359.37M
Open
77.45
52 wk Range
76.78-179.65
EPS
-5.35
Volume
527,165
Market Cap
5.22B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
409,369
P/E Ratio
-
Beta
1.7
1-Year Change
-14.49%
Shares Outstanding
67,836,060
Next Earnings Date
08 Nov 2021
What is your sentiment on Ultragenyx?
or
Market is currently closed. Voting is open during market hours.

Ultragenyx News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellSellSell
Technical IndicatorsSellStrong SellBuyStrong SellStrong Sell
SummarySellStrong SellNeutralStrong SellStrong Sell

Ultragenyx Company Profile

Ultragenyx Company Profile

Employees
893

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company's therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy and nucleic acid product candidates. Its three approved product candidates include Crysvita (burosumab), for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa), for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome and Dojolvi (triheptanoin), for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD). Its clinical product candidates include DTX401, for the treatment of glycogen storage disease type Ia (GSDIa), DTX301, for the treatment of ornithine transcarbamylase (OTC), UX143, GTX-102, UX701 and UX053.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.